Is Avatrombopag (Avatrombopag, Su Kexin) covered by medical insurance?

Avatrombopag/Avatrombopag is a drug designed to treat thrombocytopenia associated with chronic liver disease. This disease is common in adults who require planned medical or dental surgery. Avatrombopag, a thrombopoietin receptor agonist, can increase platelet production by stimulating thrombopoietin receptors in the bone marrow. In clinical applications, the drug has shown good efficacy, helping patients increase platelet counts and reduce the risk of bleeding during surgery.

Since it was first approved in May 2018, avatrombopag has obtained market access in many countries and regions. The European Union approved the use of the drug in June 2019 and Australia in January 2023. These approvals mark the gradual entry of avatrombopag into the international market as a new treatment option, providing new hope for patients with chronic liver disease. Especially in necessary medical interventions, drugs can help patients complete surgeries safely and improve their quality of life.

In China, avatrombopag was approved by the State Food and Drug Administration in April 2020 under the trade name Sukesin. The launch of this drug provides an important option for clinical treatment in China and has attracted widespread attention. However, medical insurance coverage after the drug is launched has become a common concern for patients and medical providers.

According to the latest news, avatrombopag has entered the scope of Class B medical insurance. This means that patients who meet certain conditions can enjoy policy support for medical insurance reimbursement when using the drug. Specifically, this health insurance policy mainly applies to adult patients with chronic liver disease-related thrombocytopenia who undergo elective diagnostic procedures or surgeries. The implementation of this policy will effectively reduce the financial burden on patients during the treatment process, allowing more patients to receive timely and effective treatment.

Reference materials:https://en.wikipedia.org/wiki/Avatrombopag